Dr Reddy’s Posts Surprise Q3 Loss But Strong Operating Results Boost Shares

Main Markets Strong But Compliance Issues Linger

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge for its generic NuvaRing contraceptive but the company’s shares jumped on a robust underlying performance that analysts praised as a "great set of numbers."

India_moneybox_1200x675
Strong Earnings For India's DRL • Source: Shutterstock

Dr. Reddy's Laboratories Ltd., India’s second-largest drug company, plunged unexpectedly into the red in the third financial quarter, hit by a $156.5m write-off for its generic NuvaRing (etonorgestrel/ethinyl estradiol) contraceptive. But a strong underlying performance, reflecting a string of US launches and a tight rein on costs, propelled the company’s shares to a 52-week high.

The company, which has been grappling with US regulatory compliance issues and falling product prices in the US, crashed to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia